The insider sales are small relative to market cap and coincide with equity grants, making them likely routine tax-covering transactions. Monitor for any material news (pipeline updates, partnership announcements) that could explain the timing, but this cluster alone does not warrant a bearish view. The strong historical performance of insider buys at this company is not applicable here, as this is a sell cluster.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 10 $10.42entry
- T+1 · 2mo ago −1.92%α −2.77% · $10.22
- T+5 · 2mo ago −19.00%α −19.63% · $8.44
- T+20 · 6w ago −34.74%α −37.12% · $6.80
- T+47 · todayOpen
- T+60 · in 17d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four Artiva Biotherapeutics insiders, including the CEO, COO, CTO, and CMO, sold a total of $477K in open-market shares over a one-week window. The CEO's sale of $256K represents the largest portion. These sales occurred alongside a cluster of non-cash equity grants to the same executives, suggesting the sales are likely liquidity-driven to cover tax obligations from vesting awards, rather than a bearish signal on the company's prospects.
Key Financial Metrics
Key Facts
- CEO Fred Aslan sold 23,400 shares for $256K on 2026-09-08.
- COO Jennifer Bush sold 8,400 shares for $94K on 2026-09-03.
- CTO Christopher Horan sold 10,400 shares for $116K on 2026-09-03.
- CMO Subhashis Banerjee sold 1,100 shares for $12K on 2026-09-03.
- Total insider sales of $477K represent ~0.1% of the $500M market cap.
- All four insiders also received non-cash equity grants (code A) on 2026-09-09 and 2026-09-10, suggesting sales may be tax-related.
Financial Impact
Insider sales of $477K, or ~0.1% of market cap, are trivial in size.
Risk Factors
- Insider sales could signal a lack of confidence if they accelerate or increase in size.
- The company is a pre-revenue biotech; any negative pipeline data would be highly impactful.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1789448558310 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Viewing Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers